Optimal programming management of ventricular tachycardia storm in ICD patients

Zhiyong Qian, Jianghong Guo, Zhiyong Zhang, Yao Wang, Xiaofeng Hou, Jiangang Zou

Department of Cardiology, First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu 210029, China.

Abstract

Ventricular tachycardia storm (VTS) is defined as a life-threatening syndrome of three or more separate episodes of ventricular tachycardia (VT) leading to implantable cardioverter defibrillator (ICD) therapy within 24 hours. Patients with VTS have poor outcomes and require immediate medical attention. ICD shocks have been shown to be associated with increased mortality in several studies. Optimal programming in minimization of ICD shocks may decrease mortality. Large controlled trials showed that long detection time and high heart rate detection threshold reduced ICD shock burden without an increase in syncope or death. As a fundamental therapy of ICD, antitachycardia pacing (ATP) can terminate most slow VT with a low risk of acceleration. For fast VT, burst pacing is more effective and less likely to result in acceleration than ramp pacing. One algorithm of optimal programming management during a VTS is presented in the review.

Keywords: implantable cardioverter defibrillator, optimal programming, ventricular tachycardia storm

Introduction

Implantable cardioverter defibrillator (ICD) has revolutionized the preventive treatment of patients at risk for sudden cardiac death and has been widely used for these high-risk individuals[1-3]. However, ICD does not target the pathological substrate responsible for ventricular arrhythmias. Consequently, a certain percentage of ICD recipients experience multiple episodes of ventricular tachycardia (VT) and/or ventricular fibrillation (VF) in a syndrome called ‘electrical storm’ (ES). ES is a devastating event and associated with an adverse prognosis and reduced quality of life[4]. The review focuses on VT storm (VTS) and optimal programming strategies for VTS in ICD patients.

Although there is still no consensus on formal definition of VTS, it is generally accepted that three or more separate episodes of VT leading to ICD therapies [antitachycardia pacing (ATP) or shock] over a 24 hour period constitute VTS[4-6]. The end of a VTS is defined as termination of ES without VT recurrence in two weeks[7]. No study to date has examined the threshold burden of ventricular arrhythmias which would result in an adverse outcome. Whether ventricular arrhythmias should rely on ICD therapies and how to define the time interval of separate episodes of VT are still unsettled. The definition of VTS remains empiric and is subject to amendment pending the results of large outcome studies[6].

Occurrence of VTS and its implication

In patients who have ICDs for secondary prevention of sudden cardiac death, 10%-20% will experience a
VTS within two years of ICD implantation. In contrast, the incidence is lower for primary prevention patients at 4% over an average of 20.6 months. Possible triggering factors are acute heart failure, acute myocardial ischemia, electrolyte disturbance, acute infection, and abnormal sympathetic activity. However, there are still other undetermined causes which were reported to account for 64% of VTS events.

A meta-analysis showed that ICD for secondary prevention, monomorphic VT as triggering arrhythmia, lower ejection fraction and class I anti-arrhythmic drugs were associated with ES, which could be used to define high risk populations for ES. Advanced age and male gender in ES patients had a trend towards increased prevalence, but with no statistical significance. One study observed that the combination of left ventricular ejection fraction < 25% and QRS duration > 120 ms was a powerful predictor of the occurrence of ES.

Many studies have consistently found that VTS is associated with higher mortality in both secondary and primary prophylaxis patients. A recent meta-analysis enrolling 5,912 cases showed that ES was a strong mortality risk factor, which accounted for a 3.2-fold increased risk of death and was associated with a 3.4-fold increased risk for the composite endpoint of death, heart transplantation, and hospitalization for heart failure.

The comprehensive management of VTS includes seeking and eliminating the triggering factors using sedation, anti-arrhythmic drugs, ICD programming, catheter ablation and/or cardiac sympathetic denervation. Optimization of programming to prevent unnecessary shocks is paramount to these patients.

**Optimal programming strategies of VTS in ICD patients**

The detection and treatment of ventricular arrhythmias by an ICD involves a series of sequential steps, each of which provides an opportunity to prevent unnecessary shocks (Fig. 1). These steps include heart rate detection, number of intervals to detect (NID), tachycardia detection, supraventricular tachycardia (SVT)-VT discrimination, VT confirmation, ATP, reconfirmation, and shock. During a VTS, optimal programming to minimize unnecessary shocks is discussed in detail based on the recent trials (Table 1).

**Prolongation of arrhythmia detection time**

The use of prolonged arrhythmia detection time is one programming strategy that has been widely evaluated. The prospective, multicentre, non-randomized RELEVANT (Role of Long Detection Window Programming in Patients with Left Ventricular Dysfunction, Non-ischemic Etiology in Primary Prevention Treated with a Biventricular ICD) study compared a long VT/VF detection vs. standard ICD programming (NID 30/40 vs. 12/16) and showed that longer detection time reduced overall ICD therapy burden and heart failure hospitalizations without any increase of syncope or death in primary prevention of non-ischemic heart failure patients. The PROVIDE (Programming Implantable Cardioverter Defibrillators in Patients with Primary Prevention Indication to Prolong Time to First Shock) study examined the impact of extending the detection time on VTS occurrence and mortality, and found that longer detection time significantly reduced the occurrence of VTS and mortality.

---

**Fig. 1** Overview of detection and treatment of ventricular tachyarrhythmias by implantable cardioverter defibrillator (ICD). The detection and treatment of ventricular tachyarrhythmias by an ICD involves a sequence of events which provide opportunities for optimal programming. SVT: supraventricular tachycardia; VT: ventricular tachycardia.
Shock) study reported that in a large cohort of patients, a combination of programmed parameters including higher detection rate, longer detection intervals, empiric ATP, and optimized SVT discriminators were associated with a significant reduction of ICD shock therapy with reduction in all-cause mortality and without increasing arrhythmic syncope\textsuperscript{14}. The MADIT-RIT (Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy) study was a large randomized controlled trial and included 1,500 patients\textsuperscript{15}. In this study, patients were randomly assigned to the delayed (with a 60-second delay at 170 to 199 bpm, a 12-second delay at 200 to 249 bpm, and a 2.5-second delay at \(\geq 250\) bpm) and the conventional groups. The results showed that programming with a prolonged delay was associated with reductions in inappropriate therapy and all-cause mortality. The recent ADVANCE III (Avoid Delivering Therapies for Non-sustained Arrhythmias in ICD Patients III) trial has demonstrated that the use of a long detection interval (30 out of 40 intervals), combined with ATP during charging, significantly reduces the rate of appropriate therapies (ATP and shocks) and inappropriate shocks in comparison with the standard detection interval (18 out of 24) in single, dual and triple chamber ICDs, regardless of indication\textsuperscript{16}. The ADVANCE III trial confirmed and

Table 1. Clinical trials of shock reduction programming

| Study            | Year | Cases | Follow-up time | Design | CAD (%) | Secondary prevention (%) | Detection group | Control group |
|------------------|------|-------|----------------|--------|---------|--------------------------|-----------------|--------------|
| PainFREE Rx II\textsuperscript{22} | 2004 | 634   | 11 months     | RCT    | 85      | 52                       | FVT: 188–250 bpm; NID 18/24; ATP: Shock | FVT: shock |
| PREPARE\textsuperscript{20}       | 2008 | 1391  | 1 year        | OBS    | 64      | 0                        | VF: 250 bpm; NID 30/40; FVT: 102 bpm; NID 30/40; ATP × 1 VT: 167 bpm; NID 32; monitor only | Physician tailored |
| RELEVANT\textsuperscript{13}     | 2009 | 324   | 14 months     | OBS    | 0       | 0                        | VF: 182–500 bpm; NID 30/40; FVT: 182–250 bpm; NID 30/40; ATP × 1 VT: 167–182 bpm; NID 32 | VF: NID 12/16 VT: NID 16 |
| MADIT-RIT\textsuperscript{15}    | 2012 | 1500  | 1.4 years     | RCT    | 53      | 0                        | High-rate therapy group: VF: 200 bpm; 2.5s; ATP × 1 VT: 170 bpm; monitor only Delayed group: VF: 250 bpm; 2.5s; ATP × 1 FVT: 200 bpm; 12s; ATP × 1 VT: 170 bpm; 60s; ATP × 1 | VF: 200 bpm; 1s; ATP × 1 VT: 170 bpm; 2.5s; ATP × 1 |
| ADVANCE III\textsuperscript{16}  | 2013 | 1902  | 12 months     | RCT    | 60      | 25                       | VF: 186 bpm; NID 30/40; ATP × 1 VT: 150 bpm; NID 32; monitor only | VF: 188 bpm; NID 18/24; ATP × 1 VT: 150 bpm; NID 32; monitor only |
| PROVIDE\textsuperscript{14}      | 2014 | 1670  | 530 days      | RCT    | 62      | 0                        | VF: 250 bpm; NID 12 VT2: 214 bpm; NID 18; ATP × 1 VT1: 181 bpm; NID 25; ATP × 2 | VF: 214 bpm; NID 12 VT2: 181 bpm; NID 12; ATP × 2 VT1: 150 bpm; NID 12; monitor only |
| PainFree SST\textsuperscript{18} | 2014 | 1308  | 10.6 months   | OBS    | 43      | 34                       | VF: 188 bpm (or faster if VT enabled) Primary prevention: NID 30/40; Secondary prevention: NID randomized to 19/24 vs. 30/40 SVT Limit: 230 bpm SST algorithms: ON | |

OBS: observational, nonrandomized study; RCT: randomized clinical trial; NID: number of intervals to detect; VT: ventricular tachycardia; VF: ventricular fibrillation; FVT: fast ventricular tachycardia; SVT: supraventricular tachycardia; ATP: antitachycardia pacing; CAD: coronary artery disease.
reinforced the results of MADIT-RIT in a larger and broader primary prevention ICD population. A meta-analysis including the above four trials concluded that the use of long detection time could significantly decrease the burden of inappropriate shock therapy (RR 0.50) and all-cause mortality (RR 0.77) without significant increase in the risk of syncope\textsuperscript{[17]}. The PainFree SST trial was designed to evaluate the inappropriate shock free rate at one-year post implant in primary and secondary prevention patients with single, dual and triple chamber ICDs by SmartShock Technology (SST)\textsuperscript{[18]}. The primary results showed that over 98% of the patients were free of inappropriately shocked episodes during their first year after implantation and no difference was detected between primary (1.6% with inappropriate shocks) and secondary (2.3%) prevention patients. A cohort of secondary prevention patients were randomized in a 1:1 fashion to either a standard interval (NID = 18/24) or prolonged interval (NID = 30/40) detection of VT/VF ≥ 188 bpm (VF zone). In this large randomized trial involving high-risk secondary prevention patients, longer detection intervals did not increase the risk of syncope, ensuring the safety of this programming strategy. Prolonged interval detection programming did not impact the rates of inappropriate shocks, which were low using advanced discrimination algorithms in both groups at one year.

In conclusion, the increase of detection time could prevent both inappropriate shocks (shocks for rhythms other than VT or VF) and unnecessary shocks (shocks for self-terminating episodes) in patients with VTS. However, we should closely evaluate the status of cardiac function to determine if each individual could tolerate possible risk resulted from the delayed therapy of malignant ventricular arrhythmias. Additionally, VT may recur immediately after successful ATP, which may lead to misclassification of unsuccessful ATP, and subsequent unnecessary shocks may be delivered\textsuperscript{[20]}. In some ICDs, we can decrease the number of intervals for declaring an end of episode to obtain an early definition of return to sinus rhythm.

**Increasing heart rate detection threshold**

According to the heart rate, programmable zones are strictly defined. ICDs usually provide three zones, VT, fast VT (FVT), and VF. The description of arrhythmia characteristics in ICD patients with primary and secondary prevention indications could guide the settings of programmable zones\textsuperscript{[19]}. A shorter VT cycle length (CL, 303 ± 54 ms vs. 366 ± 71 ms) and a longer SVT CL (363 ± 70 ms vs. 323 ± 75 ms) are found in patients with primary preventive ICDs compared with those with secondary prevention indications (Fig. 2). These data indicate that ICD patients of primary prevention have faster VT and smaller overlap of SVT and VT; as a result, these patients may benefit from higher rate detection zones. On the contrary, patients with a secondary prevention indication will benefit from slower detection zones and SVT-VT discrimination algorithms because of the greater overlap between SVT and VT. Several trials have investigated the strategy combined with longer detection time in primary prevention patients.

In the PREPARE (Primary Prevention Parameters Evaluation) study, detection rate was set to 182 bpm (FVT) and VF 250 bpm\textsuperscript{[20]}. In the MADIT-RIT trial, detection rate for ventricular arrhythmias was set to 200 bpm with a 2.5-second delay in the high-rate therapy group\textsuperscript{[15]}. Similarly, the PROVIDE study defined VT, FVT and VF zones as 181 bpm, 214 bpm, and 250 bpm, respectively\textsuperscript{[14]}. Consistently, these high

---

**Fig. 2 Rates of ventricular arrhythmias detected in 978 patients in whom an ICD was implanted for primary and secondary prevention.** Patients with primary preventive ICDs have a shorter cycle length of ventricular tachycardia compared with secondary preventive patients and may benefit from higher detection zones. (Cited from: Wilkoff BL, et al. J Cardiovasc Electrophysiol. 2004;15(9):1002–1009\textsuperscript{[19]} with permission)
heart rate detection groups had significant reductions in ICD shocks without an increase in syncope or death. In Mayo Clinic, the recommended detection rate of primary prevention patients is set to 200 bpm with a 5- to 9-second delay for ICD therapies [5].

Increasing the efficacy of ATP

ATP is rapid pacing at a CL shorter than VT that terminates reentrant VT by penetrating the circuit and blocking the reentry. ATP can reduce unnecessary shocks, improve quality of life, and lengthen pulse generator life. Previous studies have demonstrated that ATP terminated 85%–90% of slow VT (< 188–200 bpm) with a low risk of acceleration (1%–5%) [21]. In PainFREE Rx II (Pacing Fast Ventricular Tachycardia Reduces Shock Therapies) trial, patients were randomized to ATP followed by shock or shock alone for the treatment of FVT (188–250 bpm) [22]. The results showed that a single 8-pulse burst of ATP was successful in terminating FVT in 72% of episodes and resulted in a significant reduction in shocks with improved quality of life and low rates of VT acceleration and syncope (Fig. 3). However, recent studies showed that efficacy of ATP with longer NID was not as high as previously reported. In ADVANCE III trial, ATP efficacy for FVT (CL 240–320 ms) was 54% [generalized estimating equation (GEE) adjusted]. One latest report showed that a new automatic ATP algorithm (an initial ATP train based on heart rate history, subsequent trains based on post-ATP interval and shocks applied at timer expiry) improved ATP efficacy for FVT to 59% (GEE adjusted) [23].

ATP mode selection

ATP was usually classified as burst if all paced beats were delivered at the same CL, and ramp if the beat-to-beat pacing CL was shortened within each pacing train. Burst and ramp pacing sequences have similar efficacy.
in slow VTs\textsuperscript{[21]} For FVT with CL < 300 ms, burst is more effective and less likely to result in acceleration than ramp. One study has investigated the efficacy of four ATP modes, including burst, ramp, scan (if the pacing CL was shortened between each pacing train), and ramp/scan (if the pacing CL was shortened both between and within each pacing train). As a result, when the VT rate was > 200 bpm, ATP was less successful, Table 2. Suggested ICD programming for specific ICD indications

| Condition          | Arrhythmia       | Programming                                      |
|--------------------|------------------|--------------------------------------------------|
| Primary prevention | VF: ≥ 200 bpm    | Longer detection time or 30 of 40 NID. Use 1–2 sequences of burst. |
|                    | FVT: 170–199 bpm | Monitor only.                                    |
| Secondary prevention| VF: ≥ 200 bpm    | 30 of 40 NID. Use 1–2 sequences of burst.        |
|                    | FVT: 170–199 bpm | Use multiple sequences of ATP.                   |
|                    | VT: < 170 bpm    | Monitor only.                                    |

ICD: Implantable cardioverter defibrillator; NID: number of intervals to detect; VT: ventricular tachycardia; VF: ventricular fibrillation; FVT: fast ventricular tachycardia.

Finding out and eliminating the possible reversible factors.
Sedation; anti-arrhythmic drug use.
Preparing advanced cardiac life support.

ICD programming:
- Prolong or disable safety features.
- Prolong duration or NID, especially for primary prevention ICDs.
- Increase heart rate detection threshold, especially for primary prevention ICDs.
- Use burst or scan for FVT.
- Use 1–2 sequences of ATP for FVT.
- Use 1–3 sequences of ATP in primary prevention ICDs.
- Use multiple sequences of ATP for slow VT.
- Use multiple sequences of ATP in secondary prevention ICDs.
- Adjust RS1 or add burst+ or ramp+.
- Change to biventricular or left–ventricular pacing in biventricular ICDs.
- Increase the lower pacing rate, especially for long–pause dependent ventricular arrhythmias.
- Turn off ICD.

IABP.
Catheter ablation.
Long–term anti–arrhythmic drug use.

Fig. 4 A flowchart of optimal programming strategies during a ventricular tachycardia storm. NID: number of intervals to detect; VT: ventricular tachycardia; FVT: fast ventricular tachycardia; ATP: antitachycardia pacing; IABP: intra-aortic balloon pump.
however, burst and scan exhibited greater efficacy (81.2% and 87.1% respectively) compared with ramp (57.1%) \(^{21}\).

**Multi-site ATP**

Several studies have reported greater success with biventricular ATP. One retrospective and observational study showed that in heart failure patients with biventricular (BiV) ICD, ATP efficacy of left ventricular (LV) and BiV pacing was higher than right ventricular (RV) ATP \(^{25}\). BiV-ATP and LV-ATP were safer than RV-ATP for slow VT (150–188 bpm). The ADVANCE CRT-D trial was a randomized and controlled multicenter trial aimed at comparing the efficacy and safety of BiV- versus RV-ATP in heart failure patients treated with cardiac resynchronization therapy-defibrillator \(^{26}\). The results showed that BiV-ATP seemed to be more effective and safer in ischemic patients than RV-ATP.

**Multi-sequence ATP**

The majority of FVTs were successfully treated by one or two ATP attempts. Only a small minority of patients were responsive to >3 ATPs. Programming a high number of ATP attempts in the FVT zone is both safe and efficient and could prevent shocks in ICD recipients \(^{27\}\. One latest study demonstrated that a second burst pacing increased the effectiveness of ATP (GEE-adjusted, 63% vs. 75%) for FVT (CL 250–320 ms) and therefore, reduced the need for high-energy shocks \(^{28\}\. 

**Adjusting R-S1 interval (%RR)**

Generally, burst CL should be 85%–90% of the VT CL for FVTs and 70%–80% for slow VTs \(^{21}\). When an unsuccessful ATP occurred, analysis of the return CL is helpful to optimize ICD programming \(^{31\}\. The CL of the drive train could be shortened or an extrastimulus added at the end of the drive train (for example, “burst +” mode) in order to penetrate the circuit. If the CL of VT is unaffected, increasing the number of paced beats could facilitate penetrating the circuit by peeling away refractoriness.

**Anti-arrhythmic drug therapy**

Intensive therapy of the anti-arrhythmic drugs, especially β-blockers and amiodarone, could help decrease the VT rate and increase the ATP efficacy \(^{29}\). 

**Increasing the lower pacing rate temporally**

In some patients, overdrive pacing by increasing the lower pacing rate of the ICD may avoid the long pause after a ventricular ectopic beat, shorten the QT interval and suppress recurrent VT/VF, particularly if dual chamber pacing is available \(^{2,30}\).

Overall, during a VT storm, ICD programming should focus on minimizing shocks. **Table 2** shows the suggested optimal programming for shock reduction based on ICD indications. Importantly, safety features that a shock is applied after a programmable time window independently from ATP should be prolonged or disabled \(^{31}\). Additionally, ICD therapies are often turned off in hospitalized patients. Catheter ablation might be the only option when a VTS is refractory to programming and drug therapies. A flowchart of optimal programming management during a VTS is exhibited in **Fig. 4**.

**Conclusion**

VTS, a life-threatening emergency, is associated with poor prognosis in ICD patients and requires immediate medical attention. Optimal programming aiming at reducing inappropriate or unnecessary shocks may provide up to a 30% relative decrease in mortality with no apparent increase in the risk of syncope \(^{31\}\. During a VTS, ICD programming focuses on minimizing the frequency of shocks. Long detection time and high heart rate detection threshold are key methods, especially for primary prevention patients. ATP therapy should be intensified in many ways including ATP mode, number of sequences, and pacing sites. However, the comprehensive management of VTS including optimal pharmacological therapy, sedation, trigger or substrate ablation and denervation is comparably essential.

The optimal programming strategies from the present clinical trials are mostly aimed at ICD patients for primary prevention of sudden cardiac death. Future studies are needed to clarify the roles of different programming strategies on secondary prevention patients.

**Acknowledgment**

We thank Dr. Jian Cao (Senior principal scientist, Medtronic) for his diligent review of this manuscript.

**References**

1. Moss AJ, Zareba W, Hall WJ, et al. Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. *N Engl J Med* 2002;346(12):877–883.

2. Bardy GH, Lee KL, Mark DB, et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. *N Engl J Med* 2005;352(3):225–237.

3. Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden
Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. *Circulation* 2006;114(10):e385–484.

[4] Borne RT, Varosy PD, Masoudi FA. Implantable cardioverter-defibrillator shocks: epidemiology, outcomes, and therapeutic approaches. *JAMA Intern Med* 2013;173(10):859–865.

[5] Madhavan M, Friedman PA. Optimal programming of implantable cardiac-defibrillators. *Circulation* 2013;128(6):659–672.

[6] Gao D, Sapp JL. Electrical storm: definitions, clinical importance, and treatment. *Curr Opin Cardiol* 2013;28(1):72–79.

[7] Greene M, Newman D, Geist M, et al. Is electrical storm in ICD patients the sign of a dying heart? Outcome of patients with clusters of ventricular tachyarrhythmias. *Europace* 2000;2(3):263–269.

[8] Exner DV, Pinski SL, Wyse DG, et al. Electrical storm presages nonudden death: the antiarrhythmics versus implantable defibrillators (AVID) trial. *Circulation* 2001;103(16):2066–2071.

[9] Brigadue F, Kouakam C, Klug D, et al. Clinical predictors and prognostic significance of electrical storm in patients with implantable cardioverter defibrillators. *Eur Heart J* 2006;27(6):700–707.

[10] Guerra F, Shkoza M, Scappini L, et al. Role of electrical storm as a mortality and morbidity risk factor and its clinical predictors: a meta-analysis. *Europace* 2014;16(3):347–353.

[11] Arya A, Haghjoo M, Dehghani MR, et al. Prevalence and predictors of electrical storm in patients with implantable cardioverter-defibrillator. *Am J Cardiol* 2006;97(3):389–392.

[12] Joglar JA, Kessler DJ, Welch PJ, et al. Effects of repeated electrical defibrillations on cardiac troponin I levels. *Am J Cardiol* 1999;83(2):270–272.

[13] Gasparini M, Menozzi C, Proclemer A, et al. A simplified biventricular defibrillator with fixed long detection intervals reduces implantable cardioverter defibrillator (ICD) interventions and heart failure hospitalizations in patients with non-ischemic cardiomyopathy implanted for primary prevention: The RELEVANT study. *Eur Heart J* 2009;30(22):2758–2767.

[14] Saeed M, Hanna I, Robotis D, et al. Programming implantable cardioverter-defibrillators in patients with primary prevention indication to prolong time to first shock: results from the PROVIDE study. *J Cardiovasc Electrophysiol* 2014;25(1):52–59.

[15] Moss AJ, Schuger C, Beck CA, et al. MADIT-RIT Trial Investigators. Reduction in inappropriate therapy and mortality through ICD programming. *N Engl J Med* 2012;367(24):2275–2283.

[16] Gasparini M, Proclemer A, Klersy C, et al. Effect of long-detection interval vs. standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial. *JAMA* 2013;309(18):1903–1911.

[17] Scott PA, Silberbauer J, McDonagh TA, et al. Impact of prolonged implantable cardioverter-defibrillator arrhythmia detection times on outcomes: A meta-analysis. *Heart Rhythm* 2014;11(5):828–835.

[18] Schloss EJ, Auricchio A, Kurita T, et al. PainFree SST trial primary results: low shock rates in patients with dual and triple chamber ICDs using novel detection algorithms. *Heart Rhythm* 2013;10(5)Supplement: AB26–4.

[19] Wilkoff BL, Hess M, Young J, et al. Differences in tachyarrhythmia detection and implantable cardioverter defibrillator therapy by primary or secondary prevention indication in cardiac resynchronization therapy patients. *J Cardiovasc Electrophysiol* 2004;15(9):1002–1009.

[20] Wilkoff BL, Williamson BD, Stern RS, et al. PREPARE Study Investigators. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. *J Am Coll Cardiol* 2008;52(7):541–550.

[21] Sweeney MO. Antitachycardia pacing for ventricular tachycardia using implantable cardioverter defibrillators: Substrates, methods and clinical experience. *Pacing Clin Electrophysiol* 2004;27(9):1292–1305.

[22] Wathen MS, DeGroot PJ, Sweeney MO, et al. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: PACing fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) Trial results. *Circulation* 2004;110(17):2591–2596.

[23] Yee R, Fisher JD, Birgersdotter-Green U, et al. Performance and safety of a new automatic antitachycardia pacing algorithm based upon electrophysiologic first principles. *Heart Rhythm* 2014;11(5)Supplement:AB27–4.

[24] Dewland TA, Carter N, Jones P, et al. Influence of ventricular arrhythmia rate and device programming on antitachycardia pacing efficacy: results from the ALTITUDE study. *Heart Rhythm* 2014;11(5)Supplement: AB27-3.

[25] Haghjoo M, Hajahmadi M, Fazelifar AF, et al. Efficacy and safety of different antitachycardia pacing sites in the termination of ventricular tachycardia in patients with biventricular implantable cardioverter-defibrillator. *Europace* 2011;13(4):509–513.

[26] Gasparini M, Anselme F, Clementy J, et al. ADVANCE CRT-D Investigators. BIVentricular versus right ventricular antitachycardia pacing to terminate ventricular tachyarrhythmias in patients receiving cardiac resynchronization therapy: the ADVANCE CRT-D Trial. *Am Heart J* 2010;159(6):1116–1123.e2.

[27] Martins RP, Blangy H, Muresan L, et al. Safety and efficacy of programming a high number of antitachycardia pacing attempts for fast ventricular tachycardia: a prospective study. *Europace* 2012;14(10):1457–1464.

[28] Anguera I, Dallaglio P, Sabate X, et al. The benefit of a second burst antitachycardia sequence for fast ventricular tachycardia in patients with implantable cardioverter defibrillators. *Pacing Clin Electrophysiol* 2014;37(4):486–494.
[29] Connolly SJ, Dorian P, Roberts RS, et al. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. *JAMA* 2006;295(2):165–171.

[30] Kurisu S, Inoue I, Kawagoe T, et al. Temporary overdriving pacing as an adjunct to antiarrhythmic drug therapy for electrical storm in acute myocardial infarction. *Circ J* 2005;69(5):613–616.

[31] Tan VH, Wilton SB, Kuriachan V, et al. Impact of programming strategies aimed at reducing non-essential implantable cardioverter defibrillator therapies on mortality—a systematic review and meta-analysis. *Circ Arrhythm Electrophysiol* 2014;7(1):164–170.